• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHENG Sunan,PENG Wei,SU Weiwei,CHENG Chunlei,WANG Yonggang.Mechanism of Jiangu Jnjection in the Treatment of bone hyperplasia and rheumatoid arthritis based on network pharmacology and molecular docking[J].Journal Of Pharmaceutical Research,2022,41(10):631-638,649[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2546times   Download 3167次 QR Code for this article
Scan with your phone!
基于网络药理学与分子对接技术探讨健骨注射液治疗骨质增生及类风湿性关节炎的作用机制
郑苏楠1,彭维1,苏薇薇1,程春雷2,王永刚1
Font:Larger+|Default|Smaller-
(1.中山大学生命科学学院,广东省中药上市后质量与药效再评价工程技术研究中心/广东省热带亚热带植物资源重点实验室,广东 广州 510275;2.山东省食品药品检验研究院,山东 济南 250101)
摘要:
目的 利用网络药理学方法研究健骨注射液治疗骨质增生及风湿性关节炎的作用机制。方法 采用超快速高效液相色谱串联三重四级杆飞行时间质谱(UFLC-Triple TOF-MS/MS)对健骨注射液的化学成分进行分析,通过中药系统药理数据库与分析平台(TCMSP)、Swiss Target Prediction数据库检索并预测健骨注射液有效成分对应靶点。通过Genecards数据库检索疾病相关靶点。利用cytoscape软件进行网络构建,将潜在作用靶点录入STRING平台构建靶点间的蛋白相互作用(PPI) 网络。采用DAVID数据库对潜在作用靶点进行GO富集分析和KEGG通路富集分析。结果 通过筛选得到15种活性成分,检索并预测得到261个对应靶点。利用在线网站Venny 2.1.0筛选出53个成分和疾病的交集靶点,涉及信号通路包括癌症通路、美洲锥虫病、TNF信号通路、T细胞受体信号通路等。分子对接结果显示,健骨注射液关键成分与核心靶蛋白均能较好结合。结论 本研究发现健骨注射液通过多成分多靶点对疾病进行调控,为后续研究提供了指导意义。
关键词:  中药注射液  骨质疏松  风湿性关节炎  网络药理学  分子对接
DOI:10.13506/j.cnki.jpr.2022.10.001
基金项目:中山大学横向科研课题(No.20163300071011019)
Mechanism of Jiangu Jnjection in the Treatment of bone hyperplasia and rheumatoid arthritis based on network pharmacology and molecular docking
ZHENG Sunan1,PENG Wei1,SU Weiwei1,CHENG Chunlei2,WANG Yonggang1
(1. Guangdong Engineering and Technology Research Center for Quality and Efficacy Re-evaluation of Post-marketed TCM, Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China; 2. Shandong Institute for Food and Drug Control, Jinan 256603, China)
Abstract:
Objective To explore the mechanism of Jiangu Injection in the treatment of bone hyperplasia and rheumatoid arthritis by means of network pharmacology.Methods Analyze the chemical components of Jiangu Injection by ultra-fast high performance liquid chromatography tandem triple quadrupole time-of-flight mass spectrometry (UFLC-Triple TOF-MS/MS). The target corresponding to the effective ingredients of Jiangu Injection is obtained through the Traditional Chinese Medicine System Pharmacological Database and Analysis Platform (TCMSP) and the Swiss Target Prediction database. Disease-related targets are searched through Genecards database. Use Cytoscape 3.7.2 to construct the network, and enter the potential targets into the STRING platform to construct the protein interaction (PPI) network between the targets. The DAVID database was used for GO enrichment analysis and KEGG pathway enrichment analysis for potential targets. Results A total of 15 active ingredients were obtained through screening, and 261 corresponding targets were retrieved and predicted. Through the online website Venny 2.1.0, the intersection of 53 components and disease targets was screened, involving signal pathways including cancer pathway, American trypanosomiasis, TNF signaling pathway, T cell receptor signaling pathway, etc. The results of molecular docking showed that the key components of Jiangu injection and the core target protein can be combined well. Conclusion This study found that Jiangu Injection regulates diseases through multiple components and multiple targets, which provides guidance for follow-up research.
Key words:  :Traditional Chinese medicine injection  Osteoporosis  Rheumatoid arthritis  Network pharmacology  Molecular docking
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.